Sign In
Buy KPTI
$9.00
-0.230 (-2.49%)
At Close: Jun 03, 2026
How Intel Is Helping Accelerate the Uptake of AI in India
05:30am, Friday, 08'th May 2020
India has ushered in a data revolution, changing the financial landscape of the country and ensuring the inclusion of a larger part of the population in the digital mainstream. Indian businesses, the
Fairmount Funds Management LLC Buys Zogenix Inc, Amicus Therapeutics Inc, Axsome Therapeutics ...
12:00am, Friday, 08'th May 2020Things Look Grim For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Today's Downgrade
12:07pm, Wednesday, 06'th May 2020
Market forces rained on the parade of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shareholders today, when the analysts...
HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $40
11:06am, Wednesday, 06'th May 2020Were Hedge Funds Right About Karyopharm Therapeutics Inc (KPTI)?
11:51pm, Tuesday, 05'th May 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index wa
Karyopharm Therapeutics Inc (KPTI) Q1 2020 Earnings Call Transcript
09:30pm, Tuesday, 05'th May 2020
KPTI earnings call for the period ending March 31, 2020.
SVB Leerink Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $29
05:14pm, Tuesday, 05'th May 2020Charting a May whipsaw, S&P 500 holds key support to start worst six months seasonally
05:02pm, Tuesday, 05'th May 2020
Technically speaking, the S&P 500 has maintained key support (2,793) amid a market whipsaw to start the worst six months seasonally, writes Michael Ashbaugh.
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Misses Revenue Estimates
02:45pm, Tuesday, 05'th May 2020
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -11.43% and -15.99%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the sto
Recap: Karyopharm Therapeutics Q1 Earnings
12:11pm, Tuesday, 05'th May 2020
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) fell 9% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 28.44% year over year to ($0.78), which mi
Karyopharm Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress
11:00am, Tuesday, 05'th May 2020
Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today reported financial results for the quarter ended March 31, 2020. In addition, Karyopharm highlighted select cor
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 5.)
Arcturus Therapeutics Ltd (...
Why Karyopharm (KPTI) Might Surprise This Earnings Season
12:53pm, Monday, 04'th May 2020
Karyopharm (KPTI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
May 04, 2020 (The Expresswire) --
Global “Veterinary Oncology Market” is a comprehensive research that provides information regarding Veterinary Oncology...
